Meiji and Symphogen call time on infection research alliance
This article was originally published in Scrip
Meiji Seika Pharma and the Danish antibody venture Symphogen have agreed to end an anti-infective R&D collaboration stretching back to 2006, with the Japanese firm pointing to "changes in the market environment in the expected indications" as the main reason.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.